← back to search

Elwira Pyż

University of Tübingen · DE
Area of research
Immunology · Radiology, Nuclear Medicine and Imaging
Research interest
Research interests include Antibody, Minimal residual disease, Antibody-dependent cell-mediated cytotoxicity, Medicine, Blinatumomab, and Bispecific antibody.
h-index
—
citations
78
works
4
NIH funding
—
primary concept
—
email
✉ Find email ↗

Recent publications

Reduction of Minimal Residual Disease in Pediatric B-lineage Acute Lymphoblastic Leukemia by an Fc-optimized CD19 Antibody
Molecular Therapy 2016cited by 20position: middledoi
Abstract B144: Reduction of minimal residual disease in pediatric B-precursor acute lymphoblastic leukemia by an Fc-optimized CD19 antibody
Cancer Immunology Research 2016cited by 0position: middledoi
Characterization of a Bispecific FLT3 X CD3 Antibody in an Improved, Recombinant Format for the Treatment of Leukemia
Molecular Therapy 2015cited by 57position: middledoi
From Bedside To Bench: Molecular Benchmarking Of An Fc-Optimized CD19 Antibody Used In Treatment Of Relapsed and Refractory Pediatric B-Lineage Acute Lymphoblastic Leukemia
Blood 2013cited by 1position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Gundram Jung · German Center for Infection Research4 papers (2013–2016)Hans‐Georg Rammensee · University of Tübingen4 papers (2013–2016)Martin Hofmann · University of Tübingen4 papers (2013–2016)Ludger Große‐Hovest · University of Tübingen4 papers (2013–2016)Rupert Handgretinger · University College London3 papers (2013–2016)Friedhelm R. Schuster · Heinrich Heine University Düsseldorf3 papers (2013–2016)Steffen Aulwurm · University of Tübingen3 papers (2013–2016)Peter Lang · Temple Street Children's University Hospital3 papers (2013–2016)Patrick Schlegel · University of Regensburg3 papers (2013–2016)— · 3 papers (2013–2016)Roland Meisel · Bambino Gesù Children's Hospital2 papers (2016–2016)Ursula J. E. Seidel · University of Tübingen2 papers (2013–2016)T Nübling · University of Tübingen1 papers (2015–2015)Dominik Schmiedel · Fraunhofer Institute for Cell Therapy and Immunology1 papers (2015–2015)Michael Durben · University of Tübingen1 papers (2015–2015)— · 1 papers (2016–2016)Hans-Jörg Bühring · University of Tübingen1 papers (2015–2015)Heiko‐Manuel Teltschik · University of Tübingen1 papers (2016–2016)Martin Ebinger · German Cancer Research Center1 papers (2016–2016)Carl-Philipp Schwarze · University of Tübingen1 papers (2016–2016)